A detailed history of Harbour Investments, Inc. transactions in Cellectis S.A. stock. As of the latest transaction made, Harbour Investments, Inc. holds 6,100 shares of CLLS stock, worth $10,797. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,100
Previous 6,100 -0.0%
Holding current value
$10,797
Previous $11,000 9.09%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jul 22, 2024

BUY
$2.41 - $3.09 $14,701 - $18,849
6,100 New
6,100 $16,000
Q4 2021

Feb 16, 2022

SELL
$8.01 - $12.84 $13,184 - $21,134
-1,646 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$11.94 - $16.09 $4,525 - $6,098
379 Added 29.91%
1,646 $21,000
Q2 2021

Aug 16, 2021

SELL
$14.36 - $20.93 $11,215 - $16,346
-781 Reduced 38.13%
1,267 $20,000
Q1 2021

Aug 17, 2021

BUY
$18.19 - $33.25 $36,561 - $66,832
2,010 Added 5289.47%
2,048 $41,000
Q1 2021

May 12, 2021

BUY
$18.19 - $33.25 $691 - $1,263
38 New
38 $1,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $80.6M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.